Abstract:Abstract Several cytokines involved in inflammatory pathologies signal via the Janus kinase-signal transducer and activator of transcription pathway. Four JAKs are known: JAK1, JAK2, JAK3 and TYK2. The specific activation of JAKs and STATs determines the biological effects of each cytokine. JAK1 is involved in the signalling of ‘γc’ receptor cytokines (IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21), pro-inflammatory cytokines including IL-6, as well as IFN. The critical position of JAK1 downstream of these cytokines suggests that JAK1-selective inhibitors are comparable to non-selective ones, without the unwanted consequences of JAK2- or JAK3-blockade. JAK inhibition has led to a better understanding of the biology of synovial inflammation and bone homeostasis. Moreover, the efficacy of non-selective JAK inhibitors and novel JAK1-selective drugs in RA supports a role for JAK1 in its pathogenesis. JAK1-selective drugs are also showing promise in axial spondyloarthritis, suggesting that they may target additional regulatory pathways that impact cytokines such as TNF and IL-17A, which do not use JAKs. Additionally, evidence now supports a JAK1 predominance in the signalling of IL-6 and oncostatin M, and indirectly, of TNF in synovial fibroblasts, macrophages and endothelial cells. Notably, bone homeostasis is also dependent on cytokines relying on JAK1 signalling to promote receptor activator of NF-κB ligand expression in osteoblasts and T cells, contributing to osteoclastogenesis. Here, the contribution of JAK1 over other kinases is unclear. While beneficial effects of JAK inhibitors on bone erosion are supported by preclinical and clinical data, effects on new bone formation in axial spondyloarthritis requires additional study. CME: This supplement is CME Accredited. To receive a CME certificate of participation, you should: Read all the papers in the supplement Register or log in at www.paradigmmc.com/962 to complete and submit the post activity assessment. You must answer 70% of the questions correctly to earn credit. You will have unlimited opportunities to successfully complete the assessment. You will receive a maximum of 7.0 AMA PRA Category 1 CreditsTM upon successful completion of the assessment.

JAK1 hits a nerve

Mind over asthma

Brainstem Neurons Control Chronic Allergen-Induced Airway Hyperreactivity

Cytokines reprogram airway sensory neurons in asthma

IL-13 promotes sensory-sympathetic neurons crosstalk in asthma

Brainstem Dbh+ neurons control allergen-induced airway hyperreactivity

A γδ T cell-IL-3 axis controls allergic responses through sensory neurons

Neuronal Wiskott-Aldrich Syndrome Protein Regulates Tgf-Beta 1-Mediated Lung Vascular Permeability

Comprehensive sequencing of the lung neuroimmune landscape in response to asthmatic induction

JNK modulates RAGE/β-catenin signaling and is essential for allergic airway inflammation in asthma

Inhibition of P21-Activated Kinase 1 Attenuates the Cardinal Features of Asthma Through Suppressing the Lymph Node Homing of Dendritic Cells.

IL-31-dependent neurogenic inflammation restrains cutaneous type 2 immune response in allergic dermatitis

Airway exposure initiates peanut allergy by involving the IL-1 pathway and T follicular helper cells in mice

TLR2 Promotes Allergic Airway Inflammation Through JNK Signaling Pathway with Activation of Autophagy

PAC1 constrains type 2 inflammation through promotion of CGRP signaling in ILC2s

Pulmonary Neuroendocrine Cells Amplify Allergic Asthma Responses

JAK1: Number one in the family; number one in inflammation?

Dysregulated TGF-β Signaling Leads to Cell-Intrinsic Changes in T cell Development that Promote Allergic Inflammation

The role of JAK/STAT signaling in neutrophilic airway inflammation

Genetic priming of sensory neurons in mice that overexpress PAR2 enhances allergen responsiveness

Ezh2 controls development of natural killer T cells, which cause spontaneous asthma-like pathology